Capricor Hosts Call to Discuss Heart Complications of DMD, Its CAP-1002 Cell Therapy

Capricor Hosts Call to Discuss Heart Complications of DMD, Its CAP-1002 Cell Therapy
4
(1)

Capricor Therapeutics will host a conference call and webcast with a cardiac expert to discuss heart complications associated with Duchenne muscular dystrophy (DMD) and will also provide an update on the development of CAP-1002, its lead cell therapy candidate for people with DMD.

The event, at 1:30 p.m. EDT on April 15, will feature Michael Taylor, MD, PhD, a pediatric cardiologist at the Cincinnati Children’s Hospital Medical Center and director of Advanced Imaging Innovation and cardiac magnetic resonance at the center’s Heart Institute.

Details on how to join the call are available here, and registration to watch the webcast is here.

During the call, Taylor will give a presentation focused on cardiac complications of DMD, as well as its progression, and treatment options. He will be available at the end of his presentation to answer questions.

CAP-1002 is made up of heart progenitor cells harvested from a healthy donor, called cardiosphere-derived cells, that have regenerative properties and the ability to reduce inflammation and tissue scarring. The therapy is currently being investigated for DMD due to its potential to modify the body’s immune system in a way to promote heart repair.

A Phase 1/2 trial (NCT02485938) called HOPE showed that when administered directly into the heart, treatment with CAP-1002 was able to improve heart muscle function and reduce tissue scarring in people with DMD.

CAP-1002 is being evaluated in a Phase 2 trial (NCT03406780) called HOPE-2, which is assessing the therapy’s safety and efficacy in boys with DMD. During the trial, boys are randomly assigned to receive either CAP-1002 or a placebo, both administered by an intravenous infusion (directly into the bloodstream), every three months, for a period of one year.

Early data from HOPE-2 showed that compared to a placebo, CAP-1002 significantly improved boys’ grip strength, arm muscle function, and lung function within a period of three to six months. Mild improvements in heart function and tip-to-tip pinch strength were also reported in boys receiving CAP-1002.

“We plan to announce final 12-month data from our HOPE-2 study by the middle of the second quarter as all patient visits have now been completed,” Linda Marbán, PhD, CEO of Capricor, said in a press release. “Based on the positive results we saw at six months, we are hopeful that the data will remain strong at 12 months after active patients will have received up to four doses of CAP-1002 over the course of one year.”

“Although we recognize the challenges we all face in the midst of the international COVID-19 pandemic, we remain committed to our goal of advancing our therapeutic for patients with DMD and look forward to working with the FDA after receipt of this data with the goal of bringing this therapeutic to patients as quickly as possible,” she added.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 42
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • gene therapy
  • ATL1102 for DMD
  • casimersen NDA submitted
  • CAP-1002

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?